Literature DB >> 16213659

Algorithm for neuropathic pain treatment: an evidence based proposal.

N B Finnerup1, M Otto, H J McQuay, T S Jensen, S H Sindrup.   

Abstract

New studies of the treatment of neuropathic pain have increased the need for an updated review of randomized, double-blind, placebo-controlled trials to support an evidence based algorithm to treat neuropathic pain conditions. Available studies were identified using a MEDLINE and EMBASE search. One hundred and five studies were included. Numbers needed to treat (NNT) and numbers needed to harm (NNH) were used to compare efficacy and safety of the treatments in different neuropathic pain syndromes. The quality of each trial was assessed. Tricyclic antidepressants and the anticonvulsants gabapentin and pregabalin were the most frequently studied drug classes. In peripheral neuropathic pain, the lowest NNT was for tricyclic antidepressants, followed by opioids and the anticonvulsants gabapentin and pregabalin. For central neuropathic pain there is limited data. NNT and NNH are currently the best way to assess relative efficacy and safety, but the need for dichotomous data, which may have to be estimated retrospectively for old trials, and the methodological complexity of pooling data from small cross-over and large parallel group trials, remain as limitations.

Entities:  

Mesh:

Year:  2005        PMID: 16213659     DOI: 10.1016/j.pain.2005.08.013

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  236 in total

1.  Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain.

Authors:  Xavier Pichon; Anne S Wattiez; Carine Becamel; Ingrid Ehrlich; Joel Bockaert; Alain Eschalier; Philippe Marin; Christine Courteix
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks.

Authors:  Angela Mailis; Paul Taenzer
Journal:  Pain Res Manag       Date:  2012 May-Jun       Impact factor: 3.037

3.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

4.  Local Therapies for Localised Neuropathic Pain.

Authors:  Arun Bhaskar; Rahul Mittal
Journal:  Rev Pain       Date:  2011-06

5.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501

Review 6.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults.

Authors:  R Andrew Moore; Philip J Wiffen; Sheena Derry; Thomas Toelle; Andrew S C Rice
Journal:  Cochrane Database Syst Rev       Date:  2014-04-27

Review 7.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 8.  [Current therapy of neuropathic pain].

Authors:  M Schäfers; T R Tölle
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

Review 9.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Authors:  Hiltrud Liedgens; Nadine Hertel; Anja Gabriel; Mark Nuijten; Helen Dakin; Stephen Mitchell; Barbara Poulsen Nautrup
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.